Accelerating the development of novel gene therapies for central nervous system diseases
Cell & Gene Therapy Insights 2021; 7(4), 581–589
Published: 19 May 2021
Suyash Prasad, MBBS, MSc, MRCP, MRCPCH, FFPM
Suyash Prasad is a Pediatrician, Clinical Development Physician, Translational Scientist and Executive Leader with 20 years’ experience in the biopharmaceutical industry. He currently serves as the Chief Medical Officer and Head of Research and Development at Taysha Gene Therapies, an organization dedicated to developing AAV gene therapy approaches for treating children and adults with severe neurological disease. Suyash graduated in medicine at the University of Newcastle upon Tyne, UK where he received commendations for Pediatrics, Obstetrics and Gynecology, and Medical Ethics. His pediatric training was completed at recognized centers of excellence in the UK and Australia before he moved to industry. His industry career progressed at Eli Lilly, Genzyme, and BioMarin, and more recently he was Chief Medical Officer at the gene therapy company, Audentes Therapeutics (now Astellas Gene Therapies), before moving to Taysha. He is a UK board-certified physician and is a member of the Royal College of Physicians (MRCP) and the Royal College of Paediatrics and Child Health (MRCPCH). Suyash received his Diploma in Pharmaceutical Medicine from the Royal College of Physicians of the UK, and his Masters in Translation Science with distinction from Kings College, London. He is a Fellow of the Faculty of Pharmaceutical Medicine and is a past recipient of the Outstanding Contribution award from the Faculty. Suyash has dedicated his career to the well-being and advocacy of children who are afflicted by rare and severe disease.